BioSkryb Genomics Launches ResolveOME Early Access Program for Full Genome and Transcriptome Amplification from a Single Cell, in Conjunction with Its Innovative Bioinformatics Platform, BaseJumper

BioSkryb Genomics Launches ResolveOME Early Access Program for Full Genome and Transcriptome Amplification from a Single Cell, in Conjunction with Its Innovative Bioinformatics Platform, BaseJumperTM

  • BioSkryb launches an exclusive Early Access Program at AGBT 2022 for ResolveOME and BaseJumper, a bioinformatics platform to accelerate single-cell exploration
  • The company also recently released key data demonstrating how ResolveOME allows for the accurate assessment of single nucleotide genome scale plasticity in conjunction with transcriptional profiles

DURHAM, N.C., May 31, 2022--(BUSINESS WIRE)--BioSkryb Genomics, a biotech company developing advanced single-cell analysis tools, today announced the launch of the Early Access Program (EAP) for ResolveOME, a unified, single-cell workflow that amplifies the complete genome and full-length mRNA transcripts of the entire transcriptome from the same cell. This unification eliminated the need to split source material or interpret across datasets. Companies and researchers will have the opportunity to applyfor the EAP at the upcoming Advances in Genome Biology and Technology (AGBT) 2022 General Meeting taking place June 6-9 in Orlando. The EAP will provide first access to BioSkryb’s ResolveOME technology and BaseJumper, a bioinformatics platform to sort, analyze, and interpret very large single-cell analysis data sets.

“The ability to deeply understand the factors influencing cell heterogeneity is key to unlocking insights into disease and developing new drugs and diagnostics,” said Jay A.A. West, PhD, CEO and Cofounder of BioSkryb. “We developed ResolveOME to deliver multiple tiers of dynamic molecular information to drive novel biological insights and deliver a more complete understanding of the relationship between genotype to phenotype.”

BioSkryb recently released data demonstrating the use of ResolveOME to explore genetic drivers of tumor heterogeneity and treatment resistance. Employing even a relatively small number of individual cells ResolveOME has elucidated biomarkers of cellular variability in both the genome and transcriptome. The study highlights that both the genome and transcriptome are dynamic and plastic within individual cells, leading to a set of combinatorial alterations that affect cellular evolution. ResolveOME enables the unification of broad genomic and transcriptomic data from the same cell, driving a new understanding of the mechanisms of cellular function and differentiation.

“While we are thrilled with the performance of the ResolveOME chemistry system, what continues to surprise us is the incredible plasticity of the genome, compared to the transcriptome. In addition, using full-length mRNA transcriptional profiles from the same cells, we are able to discern the biological impact, or penetrance, of these genome modifications. Discovering genomic variation in the absence of information about transcriptional consequence of that plasticity or, conversely, a transcriptional signature without understanding underlying genomic contributions, hinders the
understanding of the molecular mechanisms of disease,” explained Dr. West. “ResolveOME provides a previously unattainable expansion of data capture and resolution, providing insights into tumor phenotype, immune evasion, and drug resistance which we expect will transform cancer drug discovery and development.”

BioSkryb’s ResolveOME and ResolveDNA TM products incorporate proprietary primary template-directed amplification (PTA) technology, which was created to address the inherent challenges of single-cell genomics by producing high-quality gene sequencing data. PTA technology employs controlled reaction parameters to uniformly amplify >95% of the genomes of single cells and low-
input samples with high precision and sensitivity, resulting in the highest quality analyses available today for any single-cell genomic applications.

“In addition to being the first to access ResolveOME, EAP partners will be enabled to leverage BaseJumper, which links a cell’s identity and genotype to identify and interpret molecular variability,” said Gary Harton, PhD, Chief Scientific Officer of BioSkryb. “While both ResolveDNA and Resolve provide an order of magnitude of improvement in sensitivity over conventional bulk sequencing methods, BaseJumper provides the ability to visualize the data in an intuitive layout which accelerates discoveries from single-cell genomics.”

During AGBT 2022, BioSkryb scientific experts will be available in the Manatee Suite, located on the lower level of Signia by Hilton Orlando Bonnet Creek. A limited number of private BaseJumper demonstrations are available and can be reserved by emailing info@bioskryb.com.

About BioSkryb Genomics

BioSkryb Genomics is a venture-backed developer of genomic amplification technologies. BioSkryb develops single-cell whole genome amplification tools to study genomic heterogeneity aiding researchers and companies in the discovery of novel insights into human disease at the cellular level. BioSkryb is headquartered in Durham, North Carolina. For more information, visit
www.bioskryb.com.

 

Company Contact: Company Contact: Gary Harton, PhD, CSO, BioSkryb, info@bioskryb.com, +1.919.370.0841 Media Contact: Jessica Yingling, PhD, Little Dog Communications Inc., jessica@litldog.com,
+1.858.344.8091

BioSkryb Genomics and ALS Automated Lab Solutions GmbH Sign U.S. Distribution Agreement to Power Unprecedented Single Cell Spatial Genomics

  • The agreement combines industry-leading technologies, enabling single cell selection and genome sequencing, and supports the development of intact tissue sample analysis
  • Together these technologies are designed to deliver breakthrough insights into in situ cellular heterogeneity to drive disease research, diagnostic and drug development, and treatment decisions

February 08, 2022 08:00 AM Eastern Standard Time

DURHAM, N.C.--(BUSINESS WIRE)--BioSkryb Genomics, a leader of single-cell genome amplification, and ALS Automated Lab Solutions GmbH, developers of a multi-patented spatial single cell and colony picking technology platform, today announced a U.S. distribution agreement to power comprehensive single cell plus spatial genomic analysis. The agreement was signed in December 2021. In addition, the partnership will develop single-cell genome analysis from intact tissue samples. The distribution agreement combines BioSkryb’s proprietary ResolveDNA™ technology with ALS CellCelector™ platform to drive single-cell genomic applications where the genome context matters.

Traditional “bulk” sequencing methods combine all cells of a tissue sample (e.g., a cancer biopsy) before sequencing and have persisted primarily due to the lack of quality DNA amplification from a single cell. Now with BioSkryb’s proprietary ResolveDNA technology combined with ALS CellCelector platform, researchers and clinicians can perform single-cell genomics from cells isolated at a specific location. The companies are collaborating to extend analysis of intact tissue specimens, where a single cell is selected from the organized cell structure and analyzed with high resolution genome analysis. This process is designed to maintain the cell context of their original environment and provides critical information for many fields, including oncology, cardiology, neurology, immunology, and preimplantation genetic testing, that could help guide diagnostics and treatment decisions.

“This will be a breakthrough for researchers and clinicians, and eventually for patients, because in one experiment, we will be able to achieve high resolution single-cell omics of critical cells, while retaining the context of where those cells interact with other cells and critical landmarks within the tissue sample,” said Jay West, Ph.D., CEO and Cofounder of BioSkryb. “With this expanded distribution agreement between BioSkryb and ALS, we will be offering an understanding of the ‘micro’ with the ‘macro” that can help accelerate genomic insights in the fields of pathology, diagnostics, and drug discovery, that can ultimately improve patient care.”

Jens Eberhardt, CEO and Cofounder of ALS added, “With this collaboration, we will enable researchers to benefit from the best in both worlds – market leading single cell isolation technology and best-in-class single cell analysis know-how and reagents. With this combined experience, we will be able to speed up knowledge and understanding of researchers and scientists that will ultimately benefit the patients soon.”

BioSkryb’s ResolveDNA products incorporate proprietary primary template-directed amplification (PTA) technology, which was created to address the inherent challenges of single-cell genomics by producing high-quality gene sequencing data. PTA technology employs controlled reaction parameters to reproducibly recover >95% of the genomes of single cells and low-input samples with high accuracy and uniformity. ResolveDNA products support sequencing library generation produced from limiting samples that have undergone whole genome amplification, resulting in the highest quality genetic analyses available today for many single-cell genomic applications.

BioSkryb Genomics will be launching an Early Access Program (EAP) for researchers to acquire the combined ALS CellCelector and ResolveDNA workflow. For more information, please visit: https://www.bioskryb.com/eap-cellcelector/

About ALS Automated Lab Solutions GmbH

ALS Automated Lab Solutions develops, manufactures and sells high-quality automated solutions for life sciences in a broad range of areas including molecular diagnostics, cancer and stem cell research, cell line development and bioprocessing. The company's core competencies are in automated cell manipulation, cell sorting and isolation, microscopic high-content imaging and analysis as well as liquid handling. The ALS CellCelector™ is the world's leading single cell and colony picking platform and is based on a multi-patented, unique cell and colony isolation technology which provides unmatched flexibility, high-quality results, operational reliability, cost-effectiveness and simple use. ALS Automated Lab Solutions GmbH is headquartered in Jena, Germany. For more information, visit www.als-jena.com.

About BioSkryb Genomics

BioSkryb Genomics is a venture-backed developer of genomic amplification technologies. BioSkryb develops single-cell whole genome amplification tools to study genomic heterogeneity and enable the development of new diagnostics for insights into human disease at the cellular level. BioSkryb is headquartered in Durham, North Carolina For more information, visit www.bioskryb.com.

 

Company Contact: Jaione Maiz, Business Development, info@bioskryb.com, +1.919.370.0841

Media Contact: Jessica Yingling, Ph.D., Little Dog Communications, jessica@litldog.com, +1.858.344.8091